AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
ConditionRelapsed/Refractory Multiple Myeloma
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorAstraZeneca
About this trial
This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.
Eligibility criteria
Qualifiers
≥18 years of age at the time of consent.
ECOG performance status of 0 or 1.
Documented diagnosis of MM per IMWG diagnostic criteria.
Participant must have received at least 3 prior lines of therapy, which include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 antibody.
Disqualifiers
Participant has a history of significant toxicity during prior CAR T-cell therapy and T-cell engaging therapy.
Participant has a history of a prior non-hematologic malignancy, unless the participant has been disease-free with no evidence of recurrence for ≥ 2 years. Some exceptions may apply.
Participant has significant cardiac, neurological, or psychiatric conditions.
Serious active or uncontrolled infection
Trial design
Treatments tested in this trial
- AZD0120
Treatment groups
182 Participants
are divided into 1 treatment groupLocations
36Alabama
Research Site35233, Birmingham United States
Arizona
Research Site85054, Phoenix United States
California
Research Site92037, La Jolla United States
Research Site90095, Los Angeles United States
Sponsors and collaborators
AstraZeneca
Lead sponsor
Source ClinicalTrials.gov